Immix Biopharma Inc Announces Promising Results of NXC201 Therapy in Multiple Myeloma Study

Retrieved on: 2023-10-02 19:01:02

Tags for this article:

Click the tags to see associated articles and topics

Immix Biopharma Inc Announces Promising Results of NXC201 Therapy in Multiple Myeloma Study. View article details on hiswai:

Excerpt

On October 2, 2023, Immix Biopharma Inc made an exciting announcement regarding the progress of their Phase 1b/2 NEXICART-1 study involving their.

Article found on: beststocks.com